Prediction of Vancomycin Levels Using Cystatin C in Overweight and Obese Patients: a Retrospective Cohort Study of Hospitalized Patients
- 16 December 2020
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 65 (1)
Abstract
The use of the kidney function biomarker cystatin C (cysC) can improve the accuracy of vancomycin dosing for target trough attainment in non-obese patients. It is unknown whether cysC can also improve vancomycin target trough attainment in overweight and obese patients. We conducted a retrospective observational study of overweight or obese hospitalized adults with stable renal function administered intravenous vancomycin between January 2011 and July 2019. Linear regression models were used to predict initial steady-state vancomycin troughs using several factors, including various cysC- and serum creatinine (SCr)-based estimates of kidney function. We compared the predicted proportion of patients within the target trough range (10-20mg/L) using the derived models to that observed from usual care. Of the 200 included patients, the mean trough level was 15 ± 6.3 mg/L. The optimal model to predict the initial trough included both cysC and SCr (R2= 0.48) rather than either biomarker alone. This model predicted 79% (95% CI: 73%-85%) of troughs could be between 10 - 20mg/L compared to the 62% observed in clinical practice (p < 0.001), a 1.3-fold increase. This study is the first to examine the role of cysC in predicting vancomycin levels in an exclusively overweight or obese population. While dosing models based on cysC appear promising in this setting, prospective validation is needed.Keywords
Funding Information
- HHS | NIH | National Institute of Allergy and Infectious Diseases (K23AI143882)
This publication has 29 references indexed in Scilit:
- Serum Cystatin C Is a Major Predictor of Vancomycin Clearance in a Population Pharmacokinetic Analysis of Patients with Normal Serum Creatinine ConcentrationsJournal of Korean Medical Science, 2013
- Estimating Glomerular Filtration Rate from Serum Creatinine and Cystatin CNew England Journal of Medicine, 2012
- Performance of a vancomycin dosage regimen developed for obese patientsAmerican Journal of Health-System Pharmacy, 2012
- Altered vancomycin pharmacokinetics in obese and morbidly obese patients: what we have learned over the past 30 yearsJournal of Antimicrobial Chemotherapy, 2012
- Use of Clinical Decision Support Systems for Kidney-Related Drug Prescribing: A Systematic ReviewAmerican Journal of Kidney Diseases, 2011
- Using Computerized Provider Order Entry and Clinical Decision Support to Improve Prescribing in Patients With Decreased GFRAmerican Journal of Kidney Diseases, 2010
- Estimating the Glomerular Filtration Rate in Obese Adult Patients for Drug DosingAdvances in Chronic Kidney Disease, 2010
- The Enterprise Data Trust at Mayo Clinic: a semantically integrated warehouse of biomedical dataJournal of the American Medical Informatics Association, 2010
- Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases PharmacistsAmerican Journal of Health-System Pharmacy, 2009
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976